Heartware closes oversubscribed
Thursday, 27 January, 2005
US artificial heart firm Heartware expects to have a market capitalisation of AUD$76.42 million when it lists on the ASX on Monday, having raised US$24.95 million (AUD$32.42 million) in an oversubscribed initial public offering.
The offer incorporates an AUD$5 million US private placement together with an Australian public offer at $0.50 per share.
Heartware is currently preparing a response to a lawsuit issued by Sydney artificial heart firm Ventracor (ASX:VCR) late last year alleging that Heartware's device infringed on the patents underlying Ventracor's ventricular assist device. The response is due by Feburary 7.
mRNA successfully delivered through blood–brain barrier
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...
Biological computer could revolutionise medical sciences
The CL1 is a commercial biological computer which fuses lab-cultivated neurons from human stem...
Genetic risk of schizophrenia impacts men and women differently
Men tend to present different clinical symptoms from women, poorer premorbid functioning and...
